The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: How successful have we been?

Annals of Oncology

Volumn 17, Issue 3, 2006, Pages 361-371

  Glynne Jones, Rob ^a   Dunst, J ^b   Sebag Montefiore, D ^c  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CELECOXIB; CETUXIMAB; CYTOTOXIC AGENT; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LEVAMISOLE; MITOMYCIN C; OXALIPLATIN; SEMUSTINE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ABSTRACT REPORT; ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; APPLICATION SITE ERYTHEMA; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLITIS; COLORECTAL CANCER; COST OF ILLNESS; CYSTITIS; DATA ANALYSIS; DEHYDRATION; DERMATITIS; DESQUAMATION; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG INFUSION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; ENZYME DEFECT; FATIGUE; GASTROINTESTINAL PAIN; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEALTH PRACTITIONER; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; LETHARGY; LEUKOPENIA; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDLINE; NAUSEA; NEUTROPENIA; NONHUMAN; ORGANIZATION; OUTCOME ASSESSMENT; PREOPERATIVE RADIOTHERAPY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROCTITIS; RADIATION DERMATITIS; RECTUM CANCER; REVIEW; SKIN MANIFESTATION; SMALL INTESTINE OBSTRUCTION; THROMBOCYTOPENIA; URINARY TRACT INFECTION; UROGENITAL TRACT DISEASE;

EID: 33644664586     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj052     Document Type: Review

References (85)

1. Cancer Facts and Figures 2004. Atlanta: American Cancer Society 2004.
2. Beets-Tan RG, Beets GL, Vliegen RF et al. Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet 2001; 357: 497-504.
3. Brown G, Radcliffe AG, Newcombe RG et al. Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. Br J Surg 2003; 90: 355-364.
4. Daniels I. MRI predicts surgical resection margin status in patients with rectal cancer: Results from the Mercury Study Group. Clin Oncol 2004; 16: S45-S46.
5. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990; 264: 1444-1450.
6. Junginger T, Hossfeld DK, Sauer R et al. Adjuvante therapie bei kolon- und rektumkarzinom. Dt Ärztebl 1999; 96: A698-700.
7. Camma C, Giunta M, Fiorica F et al. Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. JAMA 2000; 284: 1008-1015.
8. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: A systematic overview of 8507 patients from 22 randomised trials. Lancet 2001; 358: 1291-1304.
9. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740.
10. Bosset JF, Calais G, Mineur L et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results - EORTC 22921. J Clin Oncol 2005; 23: 5620-5627.
11. Chen ET, Mohiuddin M, Brodovsky H et al. Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiation. Int J Radiat Oncol Biol Phys 1994; 30: 169-175.
12. Kim HK, Jessup JM, Beard CJ et al. Locally advanced rectal carcinoma: pelvic control and morbidity following preoperative radiation therapy, resection, and intraoperative radiation therapy. Int J Radiat Oncol Biol Phys 1997; 38: 777-783.
13. Grann A, Minsky BD, Cohen AM et al. Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer. Dis Colon Rectum 1997; 40: 515-522.
14. Janjan NA, Khoo VS, Abbruzzese J et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: The M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 1999; 44: 1027-1038.
15. Mehta VK, Poen J, Ford J et al. Radiotherapy, concomitant 5-fluorouracil, and surgery for ultrasound stage T3/T4 rectal cancer. Dis Colon Rectum 2001; 44: 52-58.
16. Tjandra JJ, Reading DM, McClachan SA et al. Phase II clinical trial of preoperative combined chemoradiation for T3 and T4 resectable rectal cancer: Preliminary results. Dis Colon Rectum 2001; 44: 1113-1122.
17. Krook JE, Moertel CG, Gunderson LL et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324: 709-715.
18. Gastrointestinal Tumor Study Group. Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J Clin Oncol 1992; 10: 549-557.
19. Tepper JE, O'Connell M, Niedzwiecki D et al. Adjuvant therapy in rectal cancer: Analysis of stage, sex, and local control - final report of intergroup 0114. J Clin Oncol 2002; 20: 1744-1750.
20. Smalley SR, Benedetti J, Williamson S et al. Intergroup 0144: A phase III rectal surgical adjuvant study of pelvic radiation (XRT) plus 5FU based chemotherapy (bolus 5FU before and after PVI + XRT vs PVI before during and after XRT vs biochemically modulated bolus 5FU and XRT): mature outcome results and pelvic failure analysis. Int J Radiat Oncol Biol Phys 2004; 60 (Suppl): S137 (Abstr 14).
21. O'Connell MJ, Martenson JA, Wieand HS et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 331: 502-507.
22. Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomized, phase III trials. Br J Cancer 2004; 90: 1190-1197.
23. Cassidy J, Twelves C, Van Cutsem E et al. First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13: 566-575.
24. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-2704.
25. Scheithauer W, McKendrick J, Begbie S et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial. Annals of Oncology 2003; 14: 1735-1743.
26. Schüller J, Cassidy J, Dumont E et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45: 291-297.
27. Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274-1281.
28. Twelves C, Boyer M, Findlay M et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 2001; 37: 597-604.
29. McKendrick JJ, Cassidy J, Chakrapee-Sirisuk S et al. Capecitabine (X) is resource saving compared with i.v. bolus 5-FU/LV in adjuvant chemotherapy for Dukes' C colon cancer patients: Medical resource utilization (MRU) data from a large phase III trial (X-ACT). J Clin Oncol 2004; 22 (Suppl 14S) (Abstr 3578).
30. Douillard J-Y, Twelves C, McKendrick J et al. Pharmacoeconomic analysis of capecitabine in the adjuvant setting. Results from the X-ACT trial comparing capecitabine with 5-FU/LV in patients with Dukes' C colon cancer. Ann Oncol 2004; 15 (Suppl 3): 73 (Abstr 274).
31. Sawada N, Ishikawa T, Sekiguchi F et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 1999; 5: 2948-2953.
32. Prandoni P, Bernardi E. Upper extremity deep vein thrombosis. Curr Opin Pulm Med 1999; 5: 222-226.
33. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21: 3665-3675.
34. Clark DR, Raffin TA. Infectious complications of indwelling long-term central venous catheters. Chest 1990; 97: 966-972.
35. Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001; 40: 85-104.
36. Dunst J, Reese T, Sutter T et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 2002; 20: 3983-3991.
37. Ngan SY, Michael M, Mackay J et al. A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer. Br J Cancer 2004; 91: 1019-1024.
38. Dunst J, Reese T, Debus J et al. Phase-II-study of preoperative chemoradiation with capecitabine in rectal cancer. Proc Am Soc Clin Oncol 2004; 23: 260 (Abstr 3559).
39. Lin EH, Skibber J, Delcos M et al. A Phase II study of capecitabine and concomitant boost radiotherapy (XRT) in patients (pts) with locally advanced rectal cancer (LARC). J Clin Oncol 2005; 23 (Suppl 16S): 269s (Abstr 3593).
40. Shen W, Liu Y, Ma X et al. Capecitabine (X) combined with radiotherapy in Chinese patients (pts) with advanced or relapsed rectal carcinoma. Proc Am Soc Clin Oncol 2004; 23: 287 (Abstr 3671).
41. Kocakova I, Svoboda M, Klocova K et al. Combined therapy of locally advanced rectal adenocarcinoma with capecitabine and concurrent radiotherapy. Proc Am Soc Clin Oncol 2004; 23: 299 (Abstr 3720).
42. Dupuis O, Vié B, Lledo G et al. Capecitabine (X) chemoradiation (CRT) in the preoperative treatment of patients (pts) with rectal adenocarcinomas: A phase II GERCOR trial. Proc Am Soc Clin Oncol 2004; 23: 255 (Abstr 3538).
43. Androulakis N, Kouroussis C, Kakolyris S et al. Proc Am Soc Clin Oncol 2002; 21: 121b (Abstr 2297).
44. Di Bartolomeo M, Bajetta E, Beretta E et al. Radiosensitization with capecitabine after curative surgery for rectal cancer. Proc Am Soc Clin Oncol 2003; 22: 314 (Abstr 1262).
45. De Paoli A, Chiara S, Luppi G et al. A phase II study of capecitabine (CAP) and pre-operative radiation therapy (RT) in resectable, locally advanced rectal cancer (LARC). Proc Am Soc Clin Oncol 2004; 23: 255 (Abstr 3540).
46. Veerasarn V, Phromratanapongse P, Lorvidhaya V et al. Preoperative capecitabine (X) chemoradiation is effective and well tolerated in patients (pts) with locally advanced rectal cancer (LARC): Findings from a phase I dose escalation study. Proc ESTRO 2004 (Abstr 610).
47. Chau I, Brown G, Tait D et al. A multidisciplinary approach using twelve weeks of neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision for MRI defined poor risk rectal cancer. Proc ASCO GI 2005 (Abstr 163).
48. Wong SJ, Sadasiwan C, Erickson B et al. A phase I trial of pre-operative capecitabine and concurrent radiation for locally advanced rectal cancer. Proc Am Soc Clin Oncol 2004; 23: 312 (Abstr 3771).
49. Kim J-S, Kim J-S, Cho M-L et al. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiation Oncology Biol Phys 2002; 54: 403-408.
50. Van Cutsem E, Findlay M, Osterwalder B et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study. J Clin Oncol 2000; 18: 1337-1345.
51. Cividalli A, Ceciarelli F, Livdi E et al. Radiosensitization by oxaliplatin in a mouse adenocarcinoma: Influence of treatment schedule. Int J Radiat Oncol Biol Phys 2002; 52: 1092-1109.
52. Blackstock A, Tepper J, Hess S. Oxaliplatin: In vitro and in vivo evidence of its radiation sensitizing activity. Int J Rad Oncol Biol Phys 2000; 46: 92-94.
53. Blackstock AW, Tepper JE, Case LD et al. In vitro and in vivo radiosensitization of colon cancer cells by cis-[(1R2R)-1,2-cyclohexanediamine-N,N′] [oxalato(2- -O,O′]platinum (oxaliplatin). Int J Mol Med 2002; 10 (Suppl 1): S68.
54. Sawada N, Tanaka Y, Twelves C et al. Capecitabine plus oxaliplatin (XELOX): Findings from a human colon cancer xenograft model and a phase II clinical trial in patients with metastatic colorectal cancer (MCRC). Eur J Cancer 2003; 1 (Suppl 5): S93 (Abstr 303).
55. Giacchetti S, Itzhaki M, Gruia G et al. Long-term survival of patients with unresectable colorectal liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10: 663-669.
56. de Gramont A, Banzi M, Navarro M et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: Results of the international randomized mosaic trial. Proc Am Soc Clin Oncol 2003; 22: 253 (Abstr 1015).
57. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
58. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147.
59. Grothey A, Deschler B, Kroening H et al. Phase III study of bolus 5-fluorouracil (5-FU)/ folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002; 21 (Abstr 512).
60. Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084-2091.
61. Arkenau HT, Schmoll HJ, Kubicka S et al. Infusional 5-fluorouracil/ folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): Results of the safety and efficacy analysis. J Clin Oncol 2005; 23 (Suppl 16S): 247s (Abstr 3507).
62. Sastre J, Massuti B, Tabernero JM et al. Preliminary results of a randomised phase III trial of the TTD Group comparing capecitabine and oxaliplatin (CapeOx) vs. oxaliplatin and 5-fluorouracil in continuous infusion (5-FU CI) as first line treatment in advanced or metastatic colorectal cancer (CRC). J Clin Oncol 2005; 23 (Suppl 16S): 252s (Abstr 3524).
63. Glynne-Jones R, Sebag-Montefiore D, Maughan TS et al. A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Ann Oncol 2006; 17: 50-56.
64. Rödel C, Grabenbauer GG, Papadopoulos T et al. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003; 21: 3098-3104.
65. Machiels JPP, Duck L, Honhon B et al. Phase II study of preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with locally advanced rectal adenocarcinoma: The RadiOxCape Study. Proc ASCO GI 2005 (Abstr 245).
66. Fakih MG, Rajput A, Smith JL et al. A phase I study of weekly oxaliplatin and daily capecitabine and radiation therapy (RT) in locally advanced rectal cancer (LARC). Proc ASCO GI 2005 (Abstr 213).
67. Tucci E, Algeri R, Giulianotti PC et al. Preoperative capecitabine, oxaliplatin and high-dose pelvic conformal radiotherapy in locally advanced rectal cancer (LARC). Proc Am Soc Clin Oncol 2004; 23: 282 (Abstr 3646).
68. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355: 1041-1047.
69. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
70. Guichard S, Cussac D, Hennebelle I et al. Sequence-dependence activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int J Cancer 1997; 73: 729-734.
71. Guichard S, Hennebelle I, Bugat R et al. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol 1998; 55: 667-676.
72. Saltz LB, Niedzwiecki D, Hollis D et al. Irinotecan plus fluorouracil/ leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22 (Suppl 14S): 3500.
73. Ychou M, Raoul J, Douillard J, Bugat et al. A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). Pro Am Soc Clin Oncol 2005 (Abstr 3502).
74. Van Cutsem E, Labianca R, Hossfeld D et al. PETACC 3 Randomized phase III trial comparing infused irinotecan / 5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3). Proc Am Soc Clin Oncol Late-breaking Abstracts 2005 (Abstr LBA8).
75. Cao S, Hapke G, Rustum YM. Enhanced antitumour activity of Xeloda by irinotecan in nude mice bearing human A253 and FaDu head and neck xenografts. Proc Am Assoc Cancer Res 2001; 20 (Abstr 464).
76. Tamura K, Takada M, Kawase I et al. Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts. Jpn J Cancer Res 1997; 88: 218-223.
77. Wang D-S, Ueno Y, Oyamada H et al. Enhancement of antitumour effect of y-ray irradiation in cobination with camptothecin against human colorectal adenocarcinoma. Biol Pharm Bull 1996; 19: 354-359.
78. Kennedy AS, Kwok Y, Batko-Yovino S et al. A phase I study of preoperative capecitabine, irinotecan concurrent with radiation therapy for resectable rectal cancer. Proc Am Soc Clin Oncol Gastrointestinal Cancers Symposium 2004; (Abstr 268).
79. Willeke F, Tiefenbacher U, Hochhaus A et al. Phase II trial of capecitabine and irinotecan in combination with concurrent radiotherapy for neoadjuvant treatment of locally advanced rectal cancer. J Clin Oncol 2005; 23 (Suppl 16S): 268s (Abstr 3589).
80. Gollins SW, Myint S, Levine E et al. Phase I study of radiotherapy (RT) plus concurrent irinotecan (CPT-11) and capecitabine (CAP) as preoperative downstaging treatment for locally advanced inoperable rectal cancer. J Clin Oncol 2005; 23 (Suppl 16S): 262s (Abstr 3565).
81. Becerra CR, Cho LC, Gregorcyk S et al. A phase I study with irinotecan, capecitabine and radiation therapy for patients with locally advanced or metastatic rectal cancer. Proc ASCO GI 2005 (Abstr 212).
82. Klautke G, Foitzik T, Ludwig K et al. Intensified neoadjuvant chemoradiotherapy (CRT) with capecitabine and irinotecan in patients with locally advanced rectal cancer (LARC): A phase I/II study. Proc Am Soc Clin Oncol 2004; 23: 293 (Abstr 3693).
83. Conroy T, Bonnetain F, Chapet O et al. Preoperative (preop) radiotherapy (RT) + 5FU/folinic acid (FA) in T3,4 rectal cancers: Preliminary results of the FFCD 9203 randomized trial. Proc Am Soc Clin Oncol 2004; 23: 277 (Abstr 3626).
84. Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomized trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004; 72: 15-24.
85. Roh MS, Colangelo L, Wieand H et al. Response to preoperative multimodality therapy predicts survival in patients with carcinoma of the rectum (NSABP R-03). Proc Am Soc Clin Oncol 2004; 22 (Abstr 3505).